Keyphrases
Adjusted Hazard Ratio
60%
Between-group
20%
Cardiovascular Disease
40%
Cardiovascular Mortality
20%
Cardiovascular Outcomes
100%
Cardiovascular Risk
20%
Cerebrovascular Accident
20%
Comparative Effectiveness Studies
100%
Coronary Revascularization
20%
Cox Proportional Hazards Model
20%
Cumulative Incidence
20%
Diabetes Duration
20%
Established Cardiovascular Disease
20%
Event Analysis
20%
Glimepiride
40%
Glucose Effect
20%
Glucose-lowering Drugs
40%
Glycemia
100%
Heart Failure Hospitalization
60%
Hospitalization
20%
Insulin Glargine
20%
Liraglutide
100%
Low Cardiovascular Risk
20%
Low Risk
40%
Major Adverse Cardiovascular Events
20%
Metformin
20%
Myocardial Infarction
40%
Proportional Rate
20%
Rate Ratio
40%
Recurrent Events
20%
Reduction Approach
100%
Revascularization
20%
Sitagliptin
40%
Stable Angina
20%
Treatment Group
80%
Type 2 Diabetes Mellitus (T2DM)
100%
Type 2 Diabetic Patients
20%
Unique Identifier
20%
Medicine and Dentistry
Apoplexy
40%
Cardiovascular Disease
80%
Cardiovascular Risk
20%
Cardiovascular System
100%
Cumulative Incidence
20%
Drug Therapy
40%
Effectiveness Study
100%
Glimepiride
40%
Glycon
20%
Group Therapy
80%
Hazard Ratio
60%
Heart Failure
60%
Heart Muscle Revascularization
20%
Insulin Glargine
20%
Liraglutide
100%
Maturity Onset Diabetes of the Young
100%
Myocardial Infarction
40%
Patient with Type 2 Diabetes
20%
Prevalence
20%
Proportional Hazards Model
20%
Revascularization
20%
Sitagliptin
40%
Unstable Angina Pectoris
20%
Nursing and Health Professions
Cardiovascular Disease
80%
Cardiovascular Risk
20%
Cerebrovascular Accident
20%
Drug Therapy
40%
Glimepiride
40%
Glucose Blood Level
100%
Group Therapy
80%
Hazard Ratio
60%
Heart Failure
60%
Heart Infarction
40%
Heart Muscle Revascularization
20%
Insulin Glargine
20%
Liraglutide
100%
Metformin
20%
Non Insulin Dependent Diabetes Mellitus
100%
Patient with Type 2 Diabetes
20%
Prevalence
20%
Proportional Hazards Model
20%
Rate Ratio
40%
Revascularization
20%
Sitagliptin
40%
Unstable Angina Pectoris
20%
Pharmacology, Toxicology and Pharmaceutical Science
Cardiovascular Disease
66%
Cardiovascular Risk
16%
Cerebrovascular Accident
16%
Effectiveness Study
100%
Glimepiride
33%
Heart Failure
50%
Heart Infarction
33%
Insulin Glargine
16%
Liraglutide
83%
Metformin
16%
Non Insulin Dependent Diabetes Mellitus
100%
Prevalence
16%
Sitagliptin
33%
Unstable Angina Pectoris
16%